This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Attenuated Vaccines Market

Market Insights on Attenuated Vaccines covering sales outlook, demand forecast & up-to-date key trends

Attenuated Vaccines Market by Vaccines, Indication, Route of Administration, Age Group, End User & Region - Forecast 2022 - 2032

Attenuated Vaccines Market Outlook (2022-2032)

[307 Pages Report] The attenuated vaccines market is anticipated to reflect a 6.8% forecast CAGR during the period of 2022-2032. As of 2021, the market was valued at US$ 4,170.2 Million and is likely to record a Y-o-Y growth rate of 6.7% to reach US$ 4,451.7 Million in 2022. By the end of the forthcoming decade, a market valuation of US$ 9,305.8 Million is expected for the industry.

Many government organizations undertaking initiatives to focus on immunization, is one of the major factors that is anticipated to propel the industry growth over the forecast period.”

Diseases including Tuberculosis, yellow fever, retroviral, measles, polio, and other illnesses are all prevented by live attenuated vaccinations, which in turn is expected to accelerate the market growth.

Attributes

Details

Attenuated Vaccines Market CAGR (2022 – 2032)

6.8%

Attenuated Vaccines Market (2022)

US$ 4,451.7 Million

Attenuated Vaccines Market (2032)

US$ 9,305.8 Million

Customize this Report

Let us know your requirement to get
100% FREE customization

Prominent Drivers of Attenuated Vaccines Market

Increasing Incidences of Infectious Diseases Globally to fuel the market growth

The increase in the number of people suffering from infectious diseases across the globe acts as one of the major factors driving the growth of live attenuated vaccines market. In addition, the advent of re-emerging diseases due to overuse of antibiotics, etc. is another factor that is boosting the market growth during the forecast period.

Attenuated Vaccines Market Download Report Brochure

Diseases including Tuberculosis, yellow fever, retroviral, measles, polio, and other illnesses are all prevented by live attenuated vaccinations, which in turn is expected to accelerate the market growth. The increase in the prevalence of fungal diseases globally is escalating the growth of tropical infection globally, which in turn is anticipated to augment the growth of live attenuated vaccines market. Furthermore, rise in demand for novel treatment extends profitable opportunities to the market players during the analysis period.

Government Initiatives to Propel Market Demand

Government initiatives in many nations have resulted in a considerable reduction in the number of cases of polio across the globe. A hike in funding by government to and steps taken to make vaccination compulsory for children.

Additionally, many government organizations undertaking initiatives to focus on immunization is also boosting the market growth. Further, an increase in demand for the program aiming to prevent the spread of transmission and, also to alleviate the suffering accelerate the market growth over the analysis period.

Moreover, rise in awareness, increase in population, funds by public and private organizations, advancements in the healthcare sector, and technological advancements, coupled with the rise in the number of clinical trials conducted by many pharmaceuticals industries positively affect the live attenuated vaccines market.

Key Challenges and Restraints affecting the Attenuated Vaccines Market Growth

Limited Operating Revenue for R&D

Limited operating revenue for research and development of novel drugs is one of the major factors that is expected to impede the growth of the Attenuated Vaccines Market during the forecast period. Moreover, the high cost associated with the development is another factor expected to restrain the market growth.

Low Healthcare Budget & Lack of Awareness

Low healthcare budget especially in developing regions, as well as the lack of awareness regarding the Attenuated Vaccines among the people, are some major factors that are projected to challenge the live attenuated vaccines market during the forecast period, which in turn will hamper the market growth.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Key Trends for Attenuated Vaccines Market

Adoption of Live Attenuated Vaccines for Vaccines Preparation

Live attenuated vaccines are prepared by weakening the bacterial or viral strains using stable mutations. This technology does not kill the microorganism. It removes the disease-causing ability of the microorganism. The live attenuated vaccines elicits the immune system in a vaccinated individual. Live attenuated vaccines are used to prevent diseases such as tuberculosis, yellow fever, retroviral, measles, polio, and others. Initiatives by governments of various countries has significantly decreased the number of polio cases across the world.

According to the World Health Organization (WHO), since 1988, polio cases have decreased by over 99%. In 2016, only 37 cases were reported as compared to 350,000 in 1988. Over 16 million people have been saved from paralysis attack due to polio. Failure of completely eradicate polio is likely to result in more than 200,000 new cases within 10 years.

Live attenuation technology is most widely used for vaccines preparation. This factor drives the global live attenuated vaccines market. Properties of live attenuated vaccines such as oral administration, low cost of production, prevention by pathogen, long-lasting, and high effectiveness drive the market. Tuberculosis is one of the top ten causes of death globally.

In 2015, tuberculosis accounted for 1.8 million deaths and 10.4 million people were living with the disease. Over 95% deaths due to tuberculosis were in middle- or low-income countries. In 2015, an estimated 170,000 children died and 1 million children were ill with tuberculosis. Regulatory hurdles, genetic stability, and environmental risks are likely to restrain the live attenuated vaccines market.

Comparative Analysis of the Adjacent Attenuated Vaccines Market

Attenuated Vaccines Market:

Attributes

Attenuated Vaccines Market

CAGR (2022 - 2032)

6.8%

Market Value (2032)

US$ 9,305.8 Million

Growth Factor

Adoption of live attenuated vaccines for vaccines preparation is expected to boost the market’s growth.

Opportunity

Rise in demand for novel treatment extends profitable opportunities to the market players during the analysis period.

Key Trends

A number of government organizations undertaking initiatives to focus on immunization, which is also boosting the market’s growth.

Preventive Vaccines Market:

Attributes

Preventive Vaccines Market

CAGR (2022 - 2032)

6.1%

Market Value (2032)

US$ 27.7 Billion

Growth Factor

The increasing prevalence of infectious diseases is expected to fuel the market’s growth.

Opportunity

Innovative technology in vaccines development is a major factor expected to create lucrative opportunities for the market’s growth.

Key Trends

Increased funding from government and international organizations is expected to fuel the market’s growth.

Therapeutics Vaccines Market:

Attributes

Therapeutics Vaccines Market

CAGR (2022 - 2032)

5.3%

Market Value (2032)

US$ 5.5 Billion

Growth Factor

Increasing cases of chronic diseases and need for effective treatment is acting as key driver for this market.

Opportunity

The overwhelming use of therapeutic vaccines in the healthcare sector are expected bring immense growth opportunities.

Key Trends

The increasing incidences of numerous diseases and the growing need to diagnose them at an early stage have led to tremendous advancements in the therapeutic vaccines market.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category Wise Analysis for Attenuated Vaccines Market

By Vaccines Type, which Attenuated Vaccines will witness Maximum Uptake?

Monovalent Attenuated Vaccines to register Highest Uptake

According to Future Market Insights, demand for monovalent attenuated vaccines is expected to emerge dominant. The segment is poised to accrue 72.1% of total market revenue, expected to reach a valuation of US$ 3,006.7 Million.

Monovalent vaccines generally provide immunity against a single antigen or micro-organism. Given several instances wherein administering multivalent vaccines have paved way for mutation of existing microbe strains, reliance on monovalent vaccines is expected to rise in the future.

Which Segment is likely to dominate the Market by Indication?

Chickenpox to remain dominant, Rotavirus Vaccines to gain major traction

Based on indication, attenuated vaccines for treating chickenpox will comprise bulk of the global market share, valued at 38.1%. As per FMI’s report, the segment is expected to be valued at US$ 1,588.8 Million by the end of the 2022-2032 forecast period.

Simultaneously, prospects for rotavirus treatment are likely to aggrandize, with an expected forecast CAGR of 10% until 2032. Accounting for 11.2% of the global market for attenuated vaccines, the segment is poised to reach a valuation of US$ 467.1 Million.

Region Wise Analysis for Attenuated Vaccines Market

Will North America emerge as an Attractive Attenuated Vaccines Market?

Extensive R&D and Vaccination Drives to eradicate COVID-19 have Heightened Prospects in the Region

North America is expected to provide significant expansion prospects for the attenuated vaccines market. Securing a market share of 38.7%, the region is slated to flourish at a CAGR of 5.5% during the 2022-2032 forecast period. By the end of the aforementioned decade, a market value of US$ 1,613.9 Million is anticipated for North America. Extensive R&D to discover new breakthroughs for key infectious diseases is driving market growth.

Besides initiatives taken by the government for vaccination against diseases like influenza, the market has immensely benefitted due to extensive drug discovery and vaccines research undertaken to counter the menace of COVID-19. With support from leading global players including Pfizer, Moderna and Janssen/J&J, the government has successfully deployed and vaccinated 221 Million as of May 2022, or 67% of the local population.

How Opportunistic will the Market for Attenuated Vaccines be across Asia Pacific?

India to be an Emerging Ground for Administering Attenuated Vaccines for Major Infectious Diseases

Collectively, the Asia Pacific region is expected to be highly lucrative, comprising of East Asia, South Asia and Oceania respectively. While East Asia is likely to account for 9.1% of total market value, South Asia is anticipated to be the highest revenue grosser, accounting for 12.4% of the total market, and expanding at a 10.7% value CAGR until 2032.

India is anticipated to be the chief growth driver for the market for attenuated vaccines across South Asia. In 2014, the Indian Government initiated Mission Indradhanush, an extensive immunization program covering nearly 27 Million new-born babies annually.  The Programme introduced new vaccines, including the Pneumococcal Conjugate Vaccines (PCV) and Rotavirus Vaccines (RVV). 

India’s commitment to improving access to vaccines has been a particularly important intervention in reducing child mortality and morbidity, and immunization remains a priority amongst decision-makers at the highest levels of government. Regular and effective immunization may be able to eradicate many diseases that plague India.

Who are the Key Competitors in the Attenuated Vaccines Market?

Merck & Co., Inc., GlaxoSmithKline plc. Pfizer Inc., Sanofi, Astellas Pharma, CSL Limited, Serum Institute of India Pvt. Ltd., BioDiem, AstraZeneca, Emergent BioSolutions Inc., Vivaldi Biosciences Inc., and Excavators, among others are the top companies in the global attenuated vaccines market.

With a sizable attenuated vaccines market share, these main firms are concentrating on growing their consumer base into new countries. These businesses are making use of strategic collaboration initiatives to grow their market share and profits.

Mid-size and smaller businesses, on the other hand, are expanding their market presence by gaining new contracts and entering new markets, thanks to technical developments and product innovations.

Recent Developments

  • In May 2022, Codagenix Inc., a clinical-stage synthetic biology company with a rational vaccines design platform aimed at infectious diseases and cancer, in collaboration with the Serum Institute of India Pvt. Ltd., announced that the first patient has been dosed in a U.K.-based Phase 1 clinical trial to evaluate the use of Codagenix's novel intranasal, live-attenuated virus vaccines, CoviLiv, as a booster in healthy adults following prior vaccination with approved COVID-19 vaccines.
  • In May 2022, Jynneos, a live attenuated vaccines, is being developed by the European biotech firm Bavarian Nordic. The vaccines provides immunity against smallpox and monkeypox. In addition, the symptoms are mainly managed with antibiotics and hydration therapy.
  • In May 2022, Valneva SE, a specialty vaccines company, announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya live attenuated vaccines candidate, VLA1553. The final analysis included six-month follow-up data and confirmed the topline results reported in December 2021.
  • In July 2017, Emergent BioSolutions Inc., as authorized a concurrence with Valneva SE for worldwide selective rights to Valneva's Zika antibody innovation, ZIKV. This will assist the organization with procuring income creating items and advance items to line up with accomplices, for example, Valneva to foster inventive items that could serve the requirements of both government clients and the business market.

By Key Players

Key Segments Covered in the Attenuated Vaccines Market Report

Attenuated Vaccines Market by Vaccines Type:

  • Monovalent Attenuated Vaccines
  • Multivalent Attenuated Vaccines

Attenuated Vaccines Market by Indication:

  • Attenuated Vaccines for Influenza
  • Attenuated Vaccines for Measles, Mumps & Rubella (MMR)
  • Attenuated Vaccines for Polio
  • Attenuated Vaccines for Chickenpox
  • Attenuated Vaccines for Shingles
  • Attenuated Vaccines for Rotavirus
  • Attenuated Vaccines for Other Indications

Attenuated Vaccines Market by Route of Administration:

  • Intramuscular Attenuated Vaccines Administration
  • Subcutaneous Attenuated Vaccines Administration
  • Oral Attenuated Vaccines Administration
  • Intranasal Attenuated Vaccines Administration
  • Intravenous Attenuated Vaccines Administration

Attenuated Vaccines Market by Age Group:

  • Attenuated Vaccines for Pediatrics
  • Attenuated Vaccines for Adolescents
  • Attenuated Vaccines for Adults
  • Attenuated Vaccines for Geriatric Patients

Attenuated Vaccines Market by End User:

  • Attenuated Vaccines for Hospitals
  • Attenuated Vaccines for Clinics
  • Attenuated Vaccines for Other End Users

Attenuated Vaccines Market by Region:

  • North America Attenuated Vaccines Market
  • Latin America Attenuated Vaccines Market
  • Europe Attenuated Vaccines Market
  • East Asia Attenuated Vaccines Market
  • South Asia Attenuated Vaccines Market
  • Oceania Attenuated Vaccines Market
  • Middle East & Africa Attenuated Vaccines Market

Frequently Asked Questions

According to Future Market Insights, the attenuated vaccines market was worth US$ 4,170.2 Million in 2021.

From 2012 to 2021, demand for attenuated vaccines surged at a 6.3% value CAGR.

From 2022-2032, the attenuated vaccines industry is poised to flourish at a CAGR of 6.8%.

As of 2022, the market for attenuated vaccines is poised to reach US$ 4,451.7 Million.

By 2032, sales of attenuated vaccines will likely be valued at US$ 9,305.8 Million, according to FMI.

Monovalent attenuated vaccines are expected to be most preferred, comprising over 70% of total deployment.

Attenuated vaccines for chickenpox will remain dominant, accounting for 38.1% of total market revenue.

According to FMI, North America is expected to document a 5.5% CAGR with regard to attenuated vaccines market growth.

South Asia is likely to be the most opportunistic market for attenuated vaccines in Asia, registering a 10.7% value CAGR.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity 

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Vaccine Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Bn) Analysis By Vaccine Type, 2017-2021

    5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Vaccine Type, 2022-2032

        5.3.1. Monovalent Vaccines

        5.3.2. Multivalent Vaccines

    5.4. Y-o-Y Growth Trend Analysis By Vaccine Type, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Vaccine Type, 2022-2032

6. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Bn) Analysis By Indication, 2017-2021

    6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Indication, 2022-2032

        6.3.1. Influenza 

        6.3.2. Measles, Mumps & Rubella (MMR)

        6.3.3. Polio

        6.3.4. Chickenpox

        6.3.5. Shingles

        6.3.6. Rotavirus

        6.3.7. Other Indications

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032

7. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Bn) Analysis By Route of Administration, 2017-2021

    7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Route of Administration, 2022-2032

        7.3.1. Intramuscular

        7.3.2. Subcutaneous

        7.3.3. Oral

        7.3.4. Intranasal

        7.3.5. Intravenous

    7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021

    7.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032

8. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Age Group

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Bn) Analysis By Age Group, 2017-2021

    8.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Age Group, 2022-2032

        8.3.1. Pediatric

        8.3.2. Adolcents

        8.3.3. Adults

        8.3.4. Geriatric

    8.4. Y-o-Y Growth Trend Analysis By Age Group, 2017-2021

    8.5. Absolute $ Opportunity Analysis By Age Group, 2022-2032

9. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size Value (US$ Bn) Analysis By End User, 2017-2021

    9.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By End User, 2022-2032

        9.3.1. Hospitals

        9.3.2. Clinics

        9.3.3. Others

    9.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021

    9.5. Absolute $ Opportunity Analysis By End User, 2022-2032

10. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    10.1. Introduction

    10.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021

    10.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. MEA

    10.4. Market Attractiveness Analysis By Region

11. North America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Value (US$ Bn)ed States

            11.2.1.2. Canada

        11.2.2. By Vaccine Type

        11.2.3. By Indication

        11.2.4. By Route of Administration

        11.2.5. By Age Group

        11.2.6. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Vaccine Type

        11.3.3. By Indication

        11.3.4. By Route of Administration

        11.3.5. By Age Group

        11.3.6. By End User

    11.4. Key Takeaways

12. Latin America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. Brazil

            12.2.1.2. Mexico

            12.2.1.3. Rest of Latin America

        12.2.2. By Vaccine Type

        12.2.3. By Indication

        12.2.4. By Route of Administration

        12.2.5. By Age Group

        12.2.6. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Vaccine Type

        12.3.3. By Indication

        12.3.4. By Route of Administration

        12.3.5. By Age Group

        12.3.6. By End User

    12.4. Key Takeaways

13. Europe Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. Germany

            13.2.1.2. U.K.

            13.2.1.3. France

            13.2.1.4. Spain

            13.2.1.5. Italy

            13.2.1.6. Rest of Europe

        13.2.2. By Vaccine Type

        13.2.3. By Indication

        13.2.4. By Route of Administration

        13.2.5. By Age Group

        13.2.6. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Vaccine Type

        13.3.3. By Indication

        13.3.4. By Route of Administration

        13.3.5. By Age Group

        13.3.6. By End User

    13.4. Key Takeaways

14. East Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Vaccine Type

        14.2.3. By Indication

        14.2.4. By Route of Administration

        14.2.5. By Age Group

        14.2.6. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Vaccine Type

        14.3.3. By Indication

        14.3.4. By Route of Administration

        14.3.5. By Age Group

        14.3.6. By End User

    14.4. Key Takeaways

15. South Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    15.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    15.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        15.2.1. By Country

            15.2.1.1. India

            15.2.1.2. ASEAN

            15.2.1.3. Rest of South Asia

        15.2.2. By Vaccine Type

        15.2.3. By Indication

        15.2.4. By Route of Administration

        15.2.5. By Age Group

        15.2.6. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Vaccine Type

        15.3.3. By Indication

        15.3.4. By Route of Administration

        15.3.5. By Age Group

        15.3.6. By End User

    15.4. Key Takeaways

16. Oceania Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    16.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    16.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        16.2.1. By Country

            16.2.1.1. Australia

            16.2.1.2. New Zealand

        16.2.2. By Vaccine Type

        16.2.3. By Indication

        16.2.4. By Route of Administration

        16.2.5. By Age Group

        16.2.6. By End User

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Vaccine Type

        16.3.3. By Indication

        16.3.4. By Route of Administration

        16.3.5. By Age Group

        16.3.6. By End User

    16.4. Key Takeaways

17. MEA Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    17.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    17.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        17.2.1. By Country

            17.2.1.1. GCC Countries

            17.2.1.2. South Africa

            17.2.1.3. Israel

            17.2.1.4. Rest of MEA

        17.2.2. By Vaccine Type

        17.2.3. By Indication

        17.2.4. By Route of Administration

        17.2.5. By Age Group

        17.2.6. By End User

    17.3. Market Attractiveness Analysis

        17.3.1. By Country

        17.3.2. By Vaccine Type

        17.3.3. By Indication

        17.3.4. By Route of Administration

        17.3.5. By Age Group

        17.3.6. By End User

    17.4. Key Takeaways

18. Key Countries Attenuated Vaccines Market Analysis

    18.1. Value (US$ Bn)ed States

        18.1.1. Pricing Analysis

        18.1.2. Market Share Analysis, 2021

            18.1.2.1. By Vaccine Type

            18.1.2.2. By Indication

            18.1.2.3. By Route of Administration

            18.1.2.4. By Age Group

            18.1.2.5. By End User

    18.2. Canada

        18.2.1. Pricing Analysis

        18.2.2. Market Share Analysis, 2021

            18.2.2.1. By Vaccine Type

            18.2.2.2. By Indication

            18.2.2.3. By Route of Administration

            18.2.2.4. By Age Group

            18.2.2.5. By End User

    18.3. Brazil

        18.3.1. Pricing Analysis

        18.3.2. Market Share Analysis, 2021

            18.3.2.1. By Vaccine Type

            18.3.2.2. By Indication

            18.3.2.3. By Route of Administration

            18.3.2.4. By Age Group

            18.3.2.5. By End User

    18.4. Mexico

        18.4.1. Pricing Analysis

        18.4.2. Market Share Analysis, 2021

            18.4.2.1. By Vaccine Type

            18.4.2.2. By Indication

            18.4.2.3. By Route of Administration

            18.4.2.4. By Age Group

            18.4.2.5. By End User

    18.5. Rest of Latin America

        18.5.1. Pricing Analysis

        18.5.2. Market Share Analysis, 2021

            18.5.2.1. By Vaccine Type

            18.5.2.2. By Indication

            18.5.2.3. By Route of Administration

            18.5.2.4. By Age Group

            18.5.2.5. By End User

    18.6. Germany

        18.6.1. Pricing Analysis

        18.6.2. Market Share Analysis, 2021

            18.6.2.1. By Vaccine Type

            18.6.2.2. By Indication

            18.6.2.3. By Route of Administration

            18.6.2.4. By Age Group

            18.6.2.5. By End User

    18.7. U.K.

        18.7.1. Pricing Analysis

        18.7.2. Market Share Analysis, 2021

            18.7.2.1. By Vaccine Type

            18.7.2.2. By Indication

            18.7.2.3. By Route of Administration

            18.7.2.4. By Age Group

            18.7.2.5. By End User

    18.8. France

        18.8.1. Pricing Analysis

        18.8.2. Market Share Analysis, 2021

            18.8.2.1. By Vaccine Type

            18.8.2.2. By Indication

            18.8.2.3. By Route of Administration

            18.8.2.4. By Age Group

            18.8.2.5. By End User

    18.9. Spain

        18.9.1. Pricing Analysis

        18.9.2. Market Share Analysis, 2021

            18.9.2.1. By Vaccine Type

            18.9.2.2. By Indication

            18.9.2.3. By Route of Administration

            18.9.2.4. By Age Group

            18.9.2.5. By End User

    18.10. Italy

        18.10.1. Pricing Analysis

        18.10.2. Market Share Analysis, 2021

            18.10.2.1. By Vaccine Type

            18.10.2.2. By Indication

            18.10.2.3. By Route of Administration

            18.10.2.4. By Age Group

            18.10.2.5. By End User

    18.11. Rest of Europe

        18.11.1. Pricing Analysis

        18.11.2. Market Share Analysis, 2021

            18.11.2.1. By Vaccine Type

            18.11.2.2. By Indication

            18.11.2.3. By Route of Administration

            18.11.2.4. By Age Group

            18.11.2.5. By End User

    18.12. China

        18.12.1. Pricing Analysis

        18.12.2. Market Share Analysis, 2021

            18.12.2.1. By Vaccine Type

            18.12.2.2. By Indication

            18.12.2.3. By Route of Administration

            18.12.2.4. By Age Group

            18.12.2.5. By End User

    18.13. Japan

        18.13.1. Pricing Analysis

        18.13.2. Market Share Analysis, 2021

            18.13.2.1. By Vaccine Type

            18.13.2.2. By Indication

            18.13.2.3. By Route of Administration

            18.13.2.4. By Age Group

            18.13.2.5. By End User

    18.14. South Korea

        18.14.1. Pricing Analysis

        18.14.2. Market Share Analysis, 2021

            18.14.2.1. By Vaccine Type

            18.14.2.2. By Indication

            18.14.2.3. By Route of Administration

            18.14.2.4. By Age Group

            18.14.2.5. By End User

    18.15. India

        18.15.1. Pricing Analysis

        18.15.2. Market Share Analysis, 2021

            18.15.2.1. By Vaccine Type

            18.15.2.2. By Indication

            18.15.2.3. By Route of Administration

            18.15.2.4. By Age Group

            18.15.2.5. By End User

    18.16. ASEAN

        18.16.1. Pricing Analysis

        18.16.2. Market Share Analysis, 2021

            18.16.2.1. By Vaccine Type

            18.16.2.2. By Indication

            18.16.2.3. By Route of Administration

            18.16.2.4. By Age Group

            18.16.2.5. By End User

    18.17. Rest of South Asia

        18.17.1. Pricing Analysis

        18.17.2. Market Share Analysis, 2021

            18.17.2.1. By Vaccine Type

            18.17.2.2. By Indication

            18.17.2.3. By Route of Administration

            18.17.2.4. By Age Group

            18.17.2.5. By End User

    18.18. Australia

        18.18.1. Pricing Analysis

        18.18.2. Market Share Analysis, 2021

            18.18.2.1. By Vaccine Type

            18.18.2.2. By Indication

            18.18.2.3. By Route of Administration

            18.18.2.4. By Age Group

            18.18.2.5. By End User

    18.19. New Zealand

        18.19.1. Pricing Analysis

        18.19.2. Market Share Analysis, 2021

            18.19.2.1. By Vaccine Type

            18.19.2.2. By Indication

            18.19.2.3. By Route of Administration

            18.19.2.4. By Age Group

            18.19.2.5. By End User

    18.20. GCC Countries

        18.20.1. Pricing Analysis

        18.20.2. Market Share Analysis, 2021

            18.20.2.1. By Vaccine Type

            18.20.2.2. By Indication

            18.20.2.3. By Route of Administration

            18.20.2.4. By Age Group

            18.20.2.5. By End User

    18.21. South Africa

        18.21.1. Pricing Analysis

        18.21.2. Market Share Analysis, 2021

            18.21.2.1. By Vaccine Type

            18.21.2.2. By Indication

            18.21.2.3. By Route of Administration

            18.21.2.4. By Age Group

            18.21.2.5. By End User

    18.22. Israel

        18.22.1. Pricing Analysis

        18.22.2. Market Share Analysis, 2021

            18.22.2.1. By Vaccine Type

            18.22.2.2. By Indication

            18.22.2.3. By Route of Administration

            18.22.2.4. By Age Group

            18.22.2.5. By End User

    18.23. Rest of MEA

        18.23.1. Pricing Analysis

        18.23.2. Market Share Analysis, 2021

            18.23.2.1. By Vaccine Type

            18.23.2.2. By Indication

            18.23.2.3. By Route of Administration

            18.23.2.4. By Age Group

            18.23.2.5. By End User

19. Market Structure Analysis

    19.1. Competition Dashboard

    19.2. Competition Benchmarking

    19.3. Market Share Analysis of Top Players

        19.3.1. By Regional

        19.3.2. By Vaccine Type

        19.3.3. By Indication

        19.3.4. By Route of Administration

        19.3.5. By Age Group

        19.3.6. By End User

20. Competition Analysis

    20.1. Competition Deep Dive

        20.1.1. GlaxoSmithKline

            20.1.1.1. Overview

            20.1.1.2. Product Portfolio

            20.1.1.3. Profitability by Market Segments

            20.1.1.4. Sales Footprint

            20.1.1.5. Strategy Overview

                20.1.1.5.1. Marketing Strategy

        20.1.2. Merck

            20.1.2.1. Overview

            20.1.2.2. Product Portfolio

            20.1.2.3. Profitability by Market Segments

            20.1.2.4. Sales Footprint

            20.1.2.5. Strategy Overview

                20.1.2.5.1. Marketing Strategy

        20.1.3. Pfizer

            20.1.3.1. Overview

            20.1.3.2. Product Portfolio

            20.1.3.3. Profitability by Market Segments

            20.1.3.4. Sales Footprint

            20.1.3.5. Strategy Overview

                20.1.3.5.1. Marketing Strategy

        20.1.4. Sanofi

            20.1.4.1. Overview

            20.1.4.2. Product Portfolio

            20.1.4.3. Profitability by Market Segments

            20.1.4.4. Sales Footprint

            20.1.4.5. Strategy Overview

                20.1.4.5.1. Marketing Strategy

        20.1.5. Astellas Pharma

            20.1.5.1. Overview

            20.1.5.2. Product Portfolio

            20.1.5.3. Profitability by Market Segments

            20.1.5.4. Sales Footprint

            20.1.5.5. Strategy Overview

                20.1.5.5.1. Marketing Strategy

        20.1.6. Johnson and Johnson

            20.1.6.1. Overview

            20.1.6.2. Product Portfolio

            20.1.6.3. Profitability by Market Segments

            20.1.6.4. Sales Footprint

            20.1.6.5. Strategy Overview

                20.1.6.5.1. Marketing Strategy

        20.1.7. CSL

            20.1.7.1. Overview

            20.1.7.2. Product Portfolio

            20.1.7.3. Profitability by Market Segments

            20.1.7.4. Sales Footprint

            20.1.7.5. Strategy Overview

                20.1.7.5.1. Marketing Strategy

        20.1.8. Serum Institute Of India

            20.1.8.1. Overview

            20.1.8.2. Product Portfolio

            20.1.8.3. Profitability by Market Segments

            20.1.8.4. Sales Footprint

            20.1.8.5. Strategy Overview

                20.1.8.5.1. Marketing Strategy

21. Assumptions & Acronyms Used

22. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by Region, 2017-2032

Table 2: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032

Table 3: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032

Table 4: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032

Table 5: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032

Table 6: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032

Table 7: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 8: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032

Table 9: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032

Table 10: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032

Table 11: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032

Table 12: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032

Table 13: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 14: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032

Table 15: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032

Table 16: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032

Table 17: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032

Table 18: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032

Table 19: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 20: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032

Table 21: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032

Table 22: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032

Table 23: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032

Table 24: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032

Table 25: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 26: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032

Table 27: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032

Table 28: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032

Table 29: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032

Table 30: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032

Table 31: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 32: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032

Table 33: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032

Table 34: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032

Table 35: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032

Table 36: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032

Table 37: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 38: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032

Table 39: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032

Table 40: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032

Table 41: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032

Table 42: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032

Table 43: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 44: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032

Table 45: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032

Table 46: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032

Table 47: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032

Table 48: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 1: Global Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032

Figure 2: Global Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032

Figure 3: Global Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032

Figure 4: Global Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032

Figure 5: Global Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032

Figure 6: Global Attenuated Vaccines Market Value (US$ Bn) by Region, 2022-2032

Figure 7: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by Region, 2017-2032

Figure 8: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 9: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 10: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032

Figure 11: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032

Figure 12: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032

Figure 13: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032

Figure 14: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 15: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 16: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032

Figure 17: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 18: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 19: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032

Figure 20: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032

Figure 21: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032

Figure 22: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032

Figure 23: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 24: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 25: Global Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032

Figure 26: Global Attenuated Vaccines Market Attractiveness by Indication, 2022-2032

Figure 27: Global Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032

Figure 28: Global Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032

Figure 29: Global Attenuated Vaccines Market Attractiveness by End User, 2022-2032

Figure 30: Global Attenuated Vaccines Market Attractiveness by Region, 2022-2032

Figure 31: North America Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032

Figure 32: North America Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032

Figure 33: North America Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032

Figure 34: North America Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032

Figure 35: North America Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032

Figure 36: North America Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032

Figure 37: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032

Figure 38: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 39: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 40: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032

Figure 41: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032

Figure 42: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032

Figure 43: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032

Figure 44: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 45: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 46: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032

Figure 47: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 48: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 49: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032

Figure 50: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032

Figure 51: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032

Figure 52: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032

Figure 53: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 54: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 55: North America Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032

Figure 56: North America Attenuated Vaccines Market Attractiveness by Indication, 2022-2032

Figure 57: North America Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032

Figure 58: North America Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032

Figure 59: North America Attenuated Vaccines Market Attractiveness by End User, 2022-2032

Figure 60: North America Attenuated Vaccines Market Attractiveness by Country, 2022-2032

Figure 61: Latin America Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032

Figure 62: Latin America Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032

Figure 63: Latin America Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032

Figure 64: Latin America Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032

Figure 65: Latin America Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032

Figure 66: Latin America Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032

Figure 67: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032

Figure 68: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 69: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 70: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032

Figure 71: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032

Figure 72: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032

Figure 73: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032

Figure 74: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 75: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 76: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032

Figure 77: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 78: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 79: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032

Figure 80: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032

Figure 81: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032

Figure 82: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032

Figure 83: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 84: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 85: Latin America Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032

Figure 86: Latin America Attenuated Vaccines Market Attractiveness by Indication, 2022-2032

Figure 87: Latin America Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032

Figure 88: Latin America Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032

Figure 89: Latin America Attenuated Vaccines Market Attractiveness by End User, 2022-2032

Figure 90: Latin America Attenuated Vaccines Market Attractiveness by Country, 2022-2032

Figure 91: Europe Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032

Figure 92: Europe Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032

Figure 93: Europe Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032

Figure 94: Europe Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032

Figure 95: Europe Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032

Figure 96: Europe Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032

Figure 97: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032

Figure 98: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 99: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 100: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032

Figure 101: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032

Figure 102: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032

Figure 103: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032

Figure 104: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 105: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 106: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032

Figure 107: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 108: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 109: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032

Figure 110: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032

Figure 111: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032

Figure 112: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032

Figure 113: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 114: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 115: Europe Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032

Figure 116: Europe Attenuated Vaccines Market Attractiveness by Indication, 2022-2032

Figure 117: Europe Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032

Figure 118: Europe Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032

Figure 119: Europe Attenuated Vaccines Market Attractiveness by End User, 2022-2032

Figure 120: Europe Attenuated Vaccines Market Attractiveness by Country, 2022-2032

Figure 121: East Asia Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032

Figure 122: East Asia Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032

Figure 123: East Asia Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032

Figure 124: East Asia Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032

Figure 125: East Asia Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032

Figure 126: East Asia Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032

Figure 127: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032

Figure 128: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 129: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 130: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032

Figure 131: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032

Figure 132: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032

Figure 133: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032

Figure 134: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 135: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 136: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032

Figure 137: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 138: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 139: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032

Figure 140: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032

Figure 141: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032

Figure 142: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032

Figure 143: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 144: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 145: East Asia Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032

Figure 146: East Asia Attenuated Vaccines Market Attractiveness by Indication, 2022-2032

Figure 147: East Asia Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032

Figure 148: East Asia Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032

Figure 149: East Asia Attenuated Vaccines Market Attractiveness by End User, 2022-2032

Figure 150: East Asia Attenuated Vaccines Market Attractiveness by Country, 2022-2032

Figure 151: South Asia Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032

Figure 152: South Asia Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032

Figure 153: South Asia Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032

Figure 154: South Asia Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032

Figure 155: South Asia Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032

Figure 156: South Asia Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032

Figure 157: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032

Figure 158: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 159: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 160: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032

Figure 161: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032

Figure 162: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032

Figure 163: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032

Figure 164: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 165: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 166: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032

Figure 167: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 168: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 169: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032

Figure 170: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032

Figure 171: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032

Figure 172: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032

Figure 173: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 174: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 175: South Asia Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032

Figure 176: South Asia Attenuated Vaccines Market Attractiveness by Indication, 2022-2032

Figure 177: South Asia Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032

Figure 178: South Asia Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032

Figure 179: South Asia Attenuated Vaccines Market Attractiveness by End User, 2022-2032

Figure 180: South Asia Attenuated Vaccines Market Attractiveness by Country, 2022-2032

Figure 181: Oceania Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032

Figure 182: Oceania Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032

Figure 183: Oceania Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032

Figure 184: Oceania Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032

Figure 185: Oceania Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032

Figure 186: Oceania Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032

Figure 187: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032

Figure 188: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 189: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 190: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032

Figure 191: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032

Figure 192: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032

Figure 193: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032

Figure 194: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 195: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 196: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032

Figure 197: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 198: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 199: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032

Figure 200: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032

Figure 201: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032

Figure 202: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032

Figure 203: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 204: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 205: Oceania Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032

Figure 206: Oceania Attenuated Vaccines Market Attractiveness by Indication, 2022-2032

Figure 207: Oceania Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032

Figure 208: Oceania Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032

Figure 209: Oceania Attenuated Vaccines Market Attractiveness by End User, 2022-2032

Figure 210: Oceania Attenuated Vaccines Market Attractiveness by Country, 2022-2032

Figure 211: MEA Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032

Figure 212: MEA Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032

Figure 213: MEA Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032

Figure 214: MEA Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032

Figure 215: MEA Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032

Figure 216: MEA Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032

Figure 217: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032

Figure 218: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 219: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 220: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032

Figure 221: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032

Figure 222: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032

Figure 223: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032

Figure 224: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 225: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 226: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032

Figure 227: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 228: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 229: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032

Figure 230: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032

Figure 231: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032

Figure 232: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032

Figure 233: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 234: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 235: MEA Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032

Figure 236: MEA Attenuated Vaccines Market Attractiveness by Indication, 2022-2032

Figure 237: MEA Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032

Figure 238: MEA Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032

Figure 239: MEA Attenuated Vaccines Market Attractiveness by End User, 2022-2032

Figure 240: MEA Attenuated Vaccines Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Companion Animals Vaccines Market

Published : January 2022

Healthcare

Anti-Infective Vaccines Market

Published : April 2016

Healthcare

Meningococcal Vaccines Market

Published : December 2021

Healthcare

Veterinary Vaccines Market

Published : February 2022

Google translate

Attenuated Vaccines Market